You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 294 No. 19, November 16, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Oncology
 •Colon Cancer
 •Gastroenterology
 •Gastrointestinal Diseases
 •Genetics
 •Genetic Counseling/ Testing/ Therapy
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Unwinding the Heterogeneous Nature of Hamartomatous Polyposis Syndromes

John M. Carethers, MD

JAMA. 2005;294:2498-2500.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In any classic "whodunit" mystery, the goal of the investigator is to find and expose the guilty party. At the onset, there may be many suspects, some of whom may appear guilty. However, the shrewd investigator picks through those distractors to clearly eliminate them and focuses on specific details to finally identify the true culprit. The same approach holds for the recognition of the hamartomatous polyposis syndromes, many of which demonstrate phenotypic features that overlap with each other.

Prior to molecular identification, phenotypic features were the sole method for disease identification, and ascertainment of future cancer risk was based on that phenotypic classification. If a patient’s clinical findings did not fall exactly into a categorized syndrome, the clinician had to use his or her best judgment based on knowledge of the known syndromes, including the patient’s potential for cancer later in life. With a modern understanding . . . [Full Text of this Article]

Author Affiliations: Department of Medicine and Rebecca and John Moores Comprehensive Cancer Center, University of California, San Diego; Veterans Administration Research Service, San Diego.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Molecular Classification of Patients With Unexplained Hamartomatous and Hyperplastic Polyposis
Kevin Sweet, Joseph Willis, Xiao-Ping Zhou, Carol Gallione, Takeshi Sawada, Pia Alhopuro, Sok Kean Khoo, Attila Patocs, Cossette Martin, Scott Bridgeman, John Heinz, Robert Pilarski, Rainer Lehtonen, Thomas W. Prior, Thierry Frebourg, Bin Tean Teh, Douglas A. Marchuk, Lauri A. Aaltonen, and Charis Eng
JAMA. 2005;294(19):2465-2473.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

RAS/ERK modulates TGF{beta}-regulated PTEN expression in human pancreatic adenocarcinoma cells
Chow et al.
Carcinogenesis 2007;28:2321-2327.
ABSTRACT | FULL TEXT  

Molecular Genetic Classification Is Useful in Patients with Polyposis
Journal Watch Dermatology 2006;2006:4-4.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.